Published in J Clin Invest on March 01, 1971
Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol (2009) 2.81
Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int (2013) 1.90
Metabolism in immunoreactive parathyroid hormone in the dog. The role of the kidney and the effects of chronic renal disease. J Clin Invest (1975) 1.70
Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest (1996) 1.63
Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest (1984) 1.44
The case for routine parathyroid hormone monitoring. Clin J Am Soc Nephrol (2012) 1.43
Influence of dietary phosphorus on renal phosphate reabsorption in the parathyroidectomized rat. J Clin Invest (1976) 1.18
Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. 3. Evaluation of parathyroid suppressibility. J Clin Invest (1973) 1.15
Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog. J Clin Invest (1978) 1.14
FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol (2013) 1.14
Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest (1989) 1.12
Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. J Clin Invest (1979) 1.05
Bone and soft tissue changes with oral phosphate supplements. J Clin Invest (1972) 1.00
Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. J Clin Invest (1977) 0.99
Correlates of parathyroid hormone concentration in hemodialysis patients. Nephrol Dial Transplant (2013) 0.95
Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest (1986) 0.93
FGF23 and PTH--double agents at the heart of CKD. Nephrol Dial Transplant (2012) 0.88
The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney Int Suppl (2011) 0.87
Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol (2011) 0.86
Neurodiagnostic abnormalities in patients with acute renal failure. J Clin Invest (1978) 0.85
Chronic kidney disease: mineral and bone disorder in children. Semin Nephrol (2013) 0.84
Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease. J Vet Emerg Crit Care (San Antonio) (2013) 0.83
The effects in the rat of varying intakes of dietary calcium, phosphorus, and hydrogen ion on hyperparathyroidism due to chronic renal failure. J Clin Invest (1974) 0.83
Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention. NDT Plus (2008) 0.80
1,25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapy. Arch Dis Child (1977) 0.79
Control of phosphate balance by the kidney and intestine. Clin Exp Nephrol (2016) 0.77
Phosphate Toxicity in CKD: The Killer among Us. Clin J Am Soc Nephrol (2016) 0.77
Changes in skeletal mineral in patients on prolonged maintenance dialysis. Br Med J (1973) 0.77
Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide. Br Med J (Clin Res Ed) (1985) 0.77
Reversal of secondary hyperparathyroidism by cimetidine in chronically uremic dogs. J Clin Invest (1981) 0.75
Hyperparathyroid bone disease in chronic renal failure. Ulster Med J (1985) 0.75
Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Int J Nephrol Renovasc Dis (2017) 0.75
Hyperphosphatemia in children receiving peritoneal dialysis--an educational program. Pediatr Nephrol (2005) 0.75
Phosphate Additive Avoidance in Chronic Kidney Disease. Diabetes Spectr (2017) 0.75
IMMUNOASSAY OF BOVINE AND HUMAN PARATHYROID HORMONE. Proc Natl Acad Sci U S A (1963) 3.31
Ionized calcium in normal serum, ultrafiltrates, and whole blood determined by ion-exchange electrodes. J Clin Invest (1970) 2.82
Parathyroid hormone in plasma in adenomatous hyperparathyroidism, uremia, and bronchogenic carcinoma. Science (1966) 2.77
Regulation of parathyroid hormone secretion: proportional control by calcium, lack of effect of phosphate. Endocrinology (1968) 2.36
The treatment of renal-glomerular osteodystrophy. Q J Med (1961) 2.18
A radioimmunoassay for parathyroid hormone in man. Proc Soc Exp Biol Med (1968) 1.91
The metabolic fate of vitamin D3-3H in chronic renal failure. J Clin Invest (1968) 1.79
Azotaemic renal osteodystrophy. Br Med Bull (1957) 1.73
Caclium, phosphorus, and bone in renal disease and transplantation. Arch Intern Med (1969) 1.66
Studies on the control of sodium excretion in experimental uremia. J Clin Invest (1969) 1.53
The role of phosphate in the secretion of parathyroid hormone in man. J Clin Invest (1970) 1.50
Application of radioimmunoassay to differentiation of adenoma and hyperplasia and to preoperative localization of hyperfunctioning parathyroid glands. N Engl J Med (1969) 1.44
Experience with a radioimmunoassay of parathyroid hormone in human sera. Trans Assoc Am Physicians (1968) 1.44
Control of phosphate excretion in uremic man. J Clin Invest (1968) 1.41
The control of phosphate excretion in uremia. J Clin Invest (1966) 1.36
Divalent ion metabolism and osteodystrophy in chronic renal failure. Yale J Biol Med (1967) 1.23
Chronic renal disease with secondary hyperparathyroidism. AMA Arch Intern Med (1959) 1.15
Finding the self? An event-related fMRI study. J Cogn Neurosci (2002) 7.99
Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A. Mol Immunol (1980) 2.98
Microtitration plate enzyme immunoassay to detect PCR-amplified DNA from Candida species in blood. J Clin Microbiol (1995) 2.75
Rapid identification of Candida species with species-specific DNA probes. J Clin Microbiol (1998) 2.65
Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A (1991) 2.44
Genetic differences between type I and type II Candida stellatoidea. Infect Immun (1989) 2.38
Nucleotide sequence analysis of the 5.8S rDNA and adjacent ITS2 region of Candida albicans and related species. Yeast (1993) 2.26
Current trends in immunodiagnosis of candidiasis and aspergillosis. Rev Infect Dis (1984) 2.22
Studies on the characteristics of the control system governing sodium excretion in uremic man. J Clin Invest (1968) 2.16
Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int (2007) 2.15
Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens. Infect Immun (1988) 2.11
Vitamin D. Am J Physiol (1999) 2.10
Cell-wall glucans of Cryptococcus neoformans Cap 67. Carbohydr Res (1990) 2.08
A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis (1999) 2.07
Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N Engl J Med (1981) 2.00
Galactomannan antigenemia in invasive aspergillosis. Infect Immun (1979) 1.94
A radioimmunoassay for parathyroid hormone in man. Proc Soc Exp Biol Med (1968) 1.91
Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest (1984) 1.88
Multiple immunoreactive molecular forms of parathyroid hormone in human serum. 1. Proc Soc Exp Biol Med (1972) 1.86
25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int (2006) 1.84
On the mechanism of the splay in the glucose titration curve in advanced experimental renal disease in the rat. J Clin Invest (1967) 1.79
Fractionation and characterization of galactoxylomannan from Cryptococcus neoformans. Carbohydr Res (1984) 1.79
The metabolic fate of vitamin D3-3H in chronic renal failure. J Clin Invest (1968) 1.79
Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women. Ann Intern Med (1988) 1.77
Detection of antibodies and antigenemia in leukemic patients with candidiasis by enzyme-linked immunosorbent assay. J Infect Dis (1981) 1.77
Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant (1999) 1.77
Serological and cellular immune activity of peptidoglucomannan fractions of Candida albicans cell walls. Infect Immun (1974) 1.76
A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol (1999) 1.71
Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporosis. Proc Natl Acad Sci U S A (1987) 1.70
Physiologic hyperparathyroidism in pregnancy. J Clin Endocrinol Metab (1972) 1.70
Metabolism in immunoreactive parathyroid hormone in the dog. The role of the kidney and the effects of chronic renal disease. J Clin Invest (1975) 1.70
Caclium, phosphorus, and bone in renal disease and transplantation. Arch Intern Med (1969) 1.66
Concomitant but not causal association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide. Infect Immun (1980) 1.65
Sequence analysis of the internal transcribed spacer 2 (ITS2) from yeast species within the genus Candida. Curr Microbiol (1998) 1.64
p21(WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int (2001) 1.63
A natriuretic factor in the serum of patients with chronic uremia. J Clin Invest (1972) 1.59
Enzyme immunoassay detection of IgM to galactoxylomannan of Cryptococcus neoformans. Diagn Immunol (1984) 1.57
Comparative serological and cutaneous reactivity of candidal cytoplasmic proteins and mannan separated by affinity for concanavalin A. J Clin Microbiol (1977) 1.56
Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies. Infect Immun (1989) 1.55
Dissociation of mannan--serum complexes and detection of Candida albicans mannan by enzyme immunoassay variations. Clin Chem (1982) 1.54
On the influence of extracellular fluid volume expansion on bicarbonate reabsorption in the rat. J Clin Invest (1969) 1.54
Studies on the control of sodium excretion in experimental uremia. J Clin Invest (1969) 1.53
The role of phosphate in the secretion of parathyroid hormone in man. J Clin Invest (1970) 1.50
Inhibition of transepithelial sodium transport in the frog skin by a low molecular weight fraction of uremic serum. J Clin Invest (1971) 1.50
Secretion and metabolic efficacy of parthyroid hormone in patients with severe hypomagnesemia. J Clin Endocrinol Metab (1974) 1.49
Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis (1997) 1.48
Activation of renal cortical adenylate cyclase by circulating immunoreactive parathyroid hormone fragments. J Clin Invest (1973) 1.47
Application of radioimmunoassay to differentiation of adenoma and hyperplasia and to preoperative localization of hyperfunctioning parathyroid glands. N Engl J Med (1969) 1.44
Experience with a radioimmunoassay of parathyroid hormone in human sera. Trans Assoc Am Physicians (1968) 1.44
Glucose titration studies in patients with chronic progressive renal disease. J Clin Invest (1967) 1.43
Control of phosphate excretion in uremic man. J Clin Invest (1968) 1.41
Comparison of enzyme immunoassay and gas-liquid chromatography for the rapid diagnosis of invasive candidiasis in cancer patients. J Clin Microbiol (1985) 1.41
Comparison of serum mannan, arabinitol, and mannose in experimental disseminated candidiasis. J Clin Microbiol (1984) 1.41
Structure determination of Cryptococcus neoformans serotype A-variant glucuronoxylomannan by 13C-n.m.r. spectroscopy. Carbohydr Res (1988) 1.41
Monoclonal antibodies against Candida tropicalis mannan: antigen detection by enzyme immunoassay and immunofluorescence. J Clin Microbiol (1986) 1.40
Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest (1973) 1.39
Circulating parathyroid hormone concentration in chronic renal insufficiency. Arch Intern Med (1969) 1.39
On the influence of extracellular fluid volume expansion and of uremia on bicarbonate reabsorption in man. J Clin Invest (1970) 1.38
Diseases associated with calcium pyrophosphate dihydrate crystal deposition. Am J Med (1974) 1.37
The control of phosphate excretion in uremia. J Clin Invest (1966) 1.36
Structural variability in the glucuronoxylomannan of Cryptococcus neoformans serotype A isolates determined by 13C NMR spectroscopy. Carbohydr Res (1992) 1.34
On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int (1972) 1.34
The presence of a natriuretic factor in urine of patients with chronic uremia. The absence of the factor in nephrotic uremic patients. J Clin Invest (1974) 1.31
In vitro assay for a humoral substance present during volume expansion and uraemia. Nature (1968) 1.30
Metabolism of bovine parathyroid hormone. Immunological and biological characteristics of fragments generated by liver perfusion. J Clin Invest (1975) 1.30
Characterization of protein and mannan polysaccharide antigens of yeasts, moulds, and actinomycetes. Curr Top Med Mycol (1985) 1.30
Comparison by ELISA of serum anti-Candida albicans mannan IgG levels of a normal population and in diseased patients. Mycopathologia (1980) 1.30
The influence of saline loading on renal glucose reabsorption in the rat. J Clin Invest (1968) 1.28
On the adaptation in sodium excretion in chronic uremia. The effects of "proportional reduction" of sodium intake. J Clin Invest (1974) 1.27
An electrophoretic karyotype for Candida albicans reveals large chromosomes in multiples. Mol Gen Genet (1987) 1.26
The peripheral metabolism of parathyroid hormone. N Engl J Med (1979) 1.26
Invasive aspergillosis: antiserum for circulating antigen produced after immunization with serum from infected rabbits. Infect Immun (1978) 1.25
Nucleotide sequence of the Candida albicans aspartyl proteinase gene. Nucleic Acids Res (1989) 1.23
Calcium and phosphate metabolism in tumoral calcinosis. Ann Intern Med (1980) 1.22
Glomerular filtration rate. Determination in patients with chronic renal disease. JAMA (1967) 1.22
Circadian rhythm in serum parathyroid hormone concentration in human subjects: correlation with serum calcium, phosphate, albumin, and growth hormone levels. J Clin Invest (1972) 1.22
Selective uptake of intact parathyroid hormone by the liver: differences between hepatic and renal uptake. J Clin Invest (1976) 1.21
1Alpha,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone secretion. J Cell Biochem (1999) 1.21
Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis (1992) 1.20